RRBP1 and ovarian carcinoma: Collectively, these integrated data demonstrate that Hes not only potentiates ADR’s anticancer activity but also mitigates its oxidative and inflammatory toxicity, suggesting that this natural compound may serve as a promising adjunctive candidate in combination chemotherapy for ovarian cancer.